Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

To evade immune destruction, tumors exploit a wide range of immune escape mechanisms, including the induction of an immunosuppressive tumor microenvironment. This is mediated, in part, by amino acid degrading enzymes indoleamine 2,3-dioxygenase, tryptophan 2,3-dioxygenase, arginase 1 and arginase 2, which have emerged as key players in the regulation of tumor-induced immune tolerance. Here we describe how the expression of tryptophan- and arginine-degrading enzymes by tumor and tumor-infiltrating cells can hamper cancer-specific immune responses, and discuss how this knowledge is being exploited to develop new strategies for cancer immunotherapy.

Original publication

DOI

10.2217/imt-2016-0118

Type

Journal article

Journal

Immunotherapy

Publication Date

01/2017

Volume

9

Pages

83 - 97

Keywords

arginase, immunosuppression, indoleamine 2,3-dioxygenase, tryptophan 2,3-dioxygenase, tumor microenvironment, Animals, Arginase, Humans, Immunity, Immunotherapy, Indoleamine-Pyrrole 2,3,-Dioxygenase, Molecular Targeted Therapy, Neoplasms, Tryptophan Oxygenase, Tumor Escape